Wobble Genomics
Wobble Genomics is a biotechnology company providing an RNA sequencing platform for the discovery of novel nucleic acid biomarkers to advance precision medicine, particularly in cancer. The company uses full-length RNA sequencing from blood to detect biomarkers that have the potential to revolutionize cancer medicine, enabling cancer to be seen in ways not previously possible. Wobble Genomics’ technology includes…
Funding snapshot
About
Wobble Genomics is a biotechnology company providing an RNA sequencing platform for the discovery of novel nucleic acid biomarkers to advance precision medicine, particularly in cancer. The company uses full-length RNA sequencing from blood to detect biomarkers that have the potential to revolutionize cancer medicine, enabling cancer to be seen in ways not previously possible. Wobble Genomics’ technology includes Level-Up, a cDNA normalization technology that allows non-targeted sequencing efficiency for biomarker discovery, and TAMA, an RNA sequencing bioinformatics software for gene detection. The platform supports applications including biomarker discovery and development, protein analysis, cancer regulatory pathways and immune activity, transcriptome discovery, and fusion gene identification. Founded in 2020 and headquartered at the Roslin Innovation Centre, Easter Bush Campus, Midlothian, United Kingdom, the company has raised approximately $12.5 million in Series A funding. Investors include Eos Advisory, IQ Capital, Mercia, DeepTech Ventures, Old College Capital, BGFG, and Edinburgh Technology. The company has approximately 19 employees.
Business model
Genomics > Genomics Research > Biomarker Discovery
Team background
College Wise > Columbia University, University of Edinburgh
Institutional investors
Backed by funds in our directory
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.